Media stories about Bristol-Myers Squibb (NYSE:BMY) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.460253726171 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Several research analysts have issued reports on BMY shares. BMO Capital Markets cut Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a report on Wednesday, May 3rd. Robert W. Baird started coverage on Bristol-Myers Squibb in a report on Tuesday, April 25th. They issued an “outperform” rating on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. Piper Jaffray Companies set a $60.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, July 27th. Finally, Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target on the stock in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $62.12.

Bristol-Myers Squibb (BMY) traded down 0.62% during trading on Friday, hitting $56.42. 4,809,885 shares of the stock traded hands. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $60.45. The company has a market capitalization of $92.52 billion, a P/E ratio of 20.61 and a beta of 1.17. The company’s 50 day moving average is $55.95 and its 200 day moving average is $54.96. Bristol-Myers Squibb also saw some unusual options trading activity on Thursday. Investors bought 781 put options on the company. This is an increase of approximately 117% compared to the average daily volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter last year, the firm posted $0.69 EPS. The company’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities analysts forecast that Bristol-Myers Squibb will post $2.98 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.